Exelixis logo

Clinical trials & pipeline

We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.

Molecules
Tumor Types
Key Trials
Phases of Development
Phase 3
CONTACT-02
Prostate Cancer
Cabozantinib + atezolizumab vs. abiraterone + prednisone or enzalutamide
Phase 3
COSMIC-313
Renal Cell Carcinoma
Cabozantinib + nivolumab + ipilimumab vs. placebo + nivolumab + ipilimumab
Phase 3
STELLAR-303
Colorectal Cancer
Zanzalintinib + atezolizumab vs. regorafenib
Phase 3
STELLAR-304
Non-Clear Cell Renal Cell Carcinoma
Zanzalintinib + nivolumab vs. sunitinib
Phase 2/3
STELLAR-305
Squamous Cell Carcinoma of Head & Neck
Zanzalintinib + pembrolizumab vs. pembrolizumab
Phase 1b/2
STELLAR-002
Multiple Solid Tumors
Zanzalintinib or zanzalintinib + nivolumab or zanzalintinib + nivolumab + ipilimumab or zanzalintinib + nivolumab + relatlimab
Phase 1b/2
STELLAR-001
Multiple Solid Tumors
Zanzalintinib or zanzalintinib + atezolizumab
Phase 1
Unnamed
Multiple Solid Tumors
XL309 or XL309 + olaparib
Phase 1
Unnamed
Multiple Solid Tumors
XB010 or XB010 + pembrolizumab
Phase 1

Sairopa*

Multiple Solid Tumors
ADU-1805 or ADU-1805 + pembrolizumab

* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805

Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

Asset/Program
  • Discovery/Preclinical Disc/Pre
  • IND IND
  • Phase 1 Phase 1
  • Phase 1b/2 Phase 1b/2
  • Pivotal Pivotal
Cabozantinib
Pivotal

CONTACT-02 (mCRPC)

CONTACT-02 (mCRPC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

Multi-TKI targeting MET/VEGFR/AXL/RET

Multi-TKI targeting MET/VEGFR/AXL/RET

Pivotal

CONTACT-02 (mCRPC)

CONTACT-02 (mCRPC)
Pivotal

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC)
Zanzalintinib
Pivotal and Phase 1b/2

STELLAR-305 (SCCHN)

STELLAR-305 (SCCHN)

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

STELLAR-303 (CRC)

STELLAR-303 (CRC)

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

Pivotal

STELLAR-305 (SCCHN)

STELLAR-305 (SCCHN)
Pivotal

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)
Pivotal

STELLAR-303 (CRC)

STELLAR-303 (CRC)
Phase 1b/2

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)
Phase 1b/2

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)
XL309
Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

USP1 inhibitor

USP1 inhibitor

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
XB010
Phase 1 and Discovery/Preclinical

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)

Next-generation 5T4-MMAE ADC

Next-generation 5T4-MMAE ADC

Phase 1

Phase 1 (Solid tumors)

Phase 1 (Solid tumors)
Discovery/Preclinical
ADU-1805
Phase 1
Sairopa*

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

SIRPα-targeting mAb

SIRPα-targeting mAb

Phase 1

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)
XL495
Discovery/Preclinical

PKMYT1 inhibitor

PKMYT1 inhibitor

Discovery/Preclinical
XB628
Discovery/Preclinical

Bispecific antibody targeting PD-L1 + NKG2A

Bispecific antibody targeting PD-L1 + NKG2A

Discovery/Preclinical
XB371
Discovery/Preclinical

Next-generation TF-TOPOi ADC

Next-generation TF-TOPOi ADC

Discovery/Preclinical
XB064
Discovery/Preclinical

ILT2-targeting mAb

ILT2-targeting mAb

Discovery/Preclinical
XB033
Discovery/Preclinical

IL13Rα2-TOPOi ADC

IL13Rα2-TOPOi ADC

Discovery/Preclinical

* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805

  • ADC = antibody-drug conjugate
  • CRC = colorectal cancer
  • ILT2 = Ig-like transcript 2
  • IL13Rα2 = interleukin 13 receptor alpha 2
  • IND = investigational new drug application
  • mAb = monoclonal antibody
  • mCRPC = metastatic castration-resistant prostate cancer
  • MMAE = monomethyl auristatin E
  • nccRCC = non-clear cell renal cell carcinoma
  • NKG2A = natural killer cell receptor group 2A
  • PD-L1 = programmed death-ligand 1
  • PKMYT1 = protein kinase, membrane associated tyrosine/threonine 1
  • RCC = renal cell carcinoma
  • SCCHN = squamous cell carcinoma of head and neck
  • SIRPα = signal regulatory protein alpha
  • TF = tissue factor
  • TKI = tyrosine kinase inhibitor
  • TOPOi = topoisomerase inhibitor
  • USP1 = ubiquitin specific peptidase 1

Disclaimer: The compounds presented are investigational or are being investigated for uses that have not been approved by the U.S. Food and Drug Administration. The safety and efficacy of these investigational compounds and/or investigational uses have not been established. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

You are now leaving the exelixis.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel Continue